160 related articles for article (PubMed ID: 24817556)
1. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.
Cai C; Liu S; Yuan Y
Stat Med; 2014 Oct; 33(23):4017-28. PubMed ID: 24817556
[TBL] [Abstract][Full Text] [Related]
2. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
Lin R; Coleman RL; Yuan Y
J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
Guo B; Yuan Y
Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
5. Monitoring event times in early phase clinical trials: some practical issues.
Thall PF; Wooten LH; Tannir NM
Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
[TBL] [Abstract][Full Text] [Related]
6. Bayesian adaptive dose-finding studies with delayed responses.
Fu H; Manner D
J Biopharm Stat; 2010 Sep; 20(5):1055-70. PubMed ID: 20721791
[TBL] [Abstract][Full Text] [Related]
7. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance.
Shen W; Ning J; Yuan Y
Stat Med; 2015 Jun; 34(13):2104-15. PubMed ID: 25756852
[TBL] [Abstract][Full Text] [Related]
8. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
9. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
10. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
12. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
Sharma P; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the rates of composite events with censored data in phase II clinical trials.
Cheung YK; Thall PF
Biometrics; 2002 Mar; 58(1):89-97. PubMed ID: 11890331
[TBL] [Abstract][Full Text] [Related]
14. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
15. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
16. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
17. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
18. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
20. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
